An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 10, 2008, Pages 989-996

  Koro, Carol E ^a   Fu, Qinggong ^a   Stender, Monika ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Myocardial infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; NITRATE; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 57649215256     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1640     Document Type: Article

References (20)

1. National Institute of Diabetes and Digestive Diseases, National Institutes of Health. National Diabetes Statistics. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm#7 [accessed 17 December 2007].
2. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
3. Adult Treatment Panel III. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-2497.
4. Koenig W. Insulin resistance, heart disease and inflammation. Identifying the 'at-risk' patient: the earlier the better? The role of inflammatory markers. Int J Clin Pract Suppl 2002; 132: 23-30.
5. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26: S33-S50.
6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformine, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
7. Sidhu JS, Cowan D, Kaski J-C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763.
8. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
9. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.
10. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957.
11. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamrua Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
12. Dormandy JA, Charbonnel B, Eckland DJA, et al. on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial In macrovascular events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
13. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2007; 298: 1180-1188.
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2470.
15. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. JAMA 2007; 298: 1189-1195.
16. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28-38.
17. Koro CE, Fu Q, Dirani RG, Fedder DO. Beneficial effects of thiazolidinediones on myocardial infarction risk in patients with type 2 diabetes. Diabetes 2004; 53: A247, Abstract 1009-P.
18. Johannes CB, Koro CE, Quinn SG, et al. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007; 16: 504-512. DOI: 10.1002/pdS.1356
19. McAfee AT, Koro CE, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711-725. DOI: 10.1002/pds.1443
20. Eng PM, Seeger JD, Loughlin J, et al. Validation of propensity score matching of ethinyl estradiol/drospirenone and other oral contraceptive initiators. Pharmacoepidemiol Drug Saf 2006; 15: S39.